2023
DOI: 10.21518/ms2023-332
|View full text |Cite
|
Sign up to set email alerts
|

Anticoagulant therapy with apixaban based on a pharmacogenetic approach: a course to safety

L. V. Fedina,
I. N. Sychev,
N. P. Denisenko
et al.

Abstract: For the past 60 years, vitamin K antagonists (VKAs) have been the main drugs used for long-term oral anticoagulant therapy. Because of the significant limitations of AVCs, direct-acting oral anticoagulants (DOAKs) have been developed over the past decade. DOAKs have a predictable pharmacokinetic profile and lack the disadvantages of vitamin K antagonists. Apixaban is an oral direct-acting factor Xa inhibitor used for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 45 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?